BioAlliance wants to create a commercial structure for selling online in Europe's drugs against rare forms of cancer while continuing its strategy of licensing agreement for its specialty products.
Judith Greciet, the future CEO of the biotechnology company, plans to strengthen the next three to five years the portfolio of drugs called "orphan" against these rare forms of cancer, which currently has three clinical stage.
The most advanced, Livatag in liver cancer, should be commercialized around 2015 while the back of clonidine Lauriad (cancer of the head and neck) should be filed "in the coming weeks" with American and European agencies to obtain the orphan drug status.
"The idea is to build a structure to market these orphan drugs. We would like to enhance this portfolio with other candidates at a later stage of their development and this is where the external growth," she said biotechnology at a forum organized by Reuters.
The company is looking for products that it could complete the development and ensure the registration and commercialization.This quest for acquisition is "active" but not advanced enough to talk, says Judith Greciet.
FUNDING FOR STUDY
The goal is to build a portfolio that allows "to generate sufficient sales to recoup a commercial structure in Europe that has about forty people," she adds.
The income provided by a direct marketing would reduce dependence vis-à-vis the current partners of the company.
The first drug of BioAlliance, Loramyc (treatment of oral fungal infections in patients with cancer or AIDS) is marketed by Therabel in Europe, In Pharmaceuticals in the U.S. and Japanese Sosei in the archipelago.
In the group's portfolio also included Aciclovir Lauriad (Sitavir), for the treatment of herpes labialis, which obtained positive results of phase III. Judith Greciet said that the dossier will be tabled for approval in the third quarter 2011 in Europe and fourth in the United States.
Discussions are under way "to find a partner to commercialize this treatment whose potential is estimated by BioAlliance between 150 and 250 million euros.
"We have contacts with European companies, U.S..Everything is open, "she said, hoping to conclude with one of them" as quickly as possible. "
Judith Greciet, currently Director General, will replace Dominique Costantini, co-founder of BioAlliance, as Director General after the general meeting on June 29
2011, YEAR HINGE
Previously she worked at Wyeth Pharmaceuticals France (now Pfizer), Pharmacia and Zeneca in 2007 before joining the Laboratory Eisai France, where she was the president.
She believes that her "vision market very, very businesslike" and "path on all commercial business" will be beneficial to a company which today has "a very R & D profile.
In 2010, the company reported operating income of $ 2.6 million after a loss of 15.5 million, on revenue of $ 22.5 million against 7.5 million.
31 March 2011, its consolidated cash was $ 16.2 million, an amount that ensures the company a year of operation
Introduced in December 2005 to 13.30 euros, the share of the company was trading at € 6.36 (2.75%) Wednesday to 11.00, after the publication of this interview.
The title of the company, whose market capitalization is $ 86.4 million, grew by 15.6%, after rising 13.40% in 2010.
The floating capital of BioAlliance totals more than 60%, the rest being in the hands of venture capital companies and banks (AGF, ING Financial Mountain, CDC).